Boston Scientific Corp (BSX)
Receivables turnover
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Revenue | US$ in thousands | 16,747,000 | 14,240,000 | 12,682,000 | 11,888,000 | 9,913,000 |
| Receivables | US$ in thousands | 2,558,000 | 2,228,000 | 1,970,000 | 1,778,000 | 1,531,000 |
| Receivables turnover | 6.55 | 6.39 | 6.44 | 6.69 | 6.47 |
December 31, 2024 calculation
Receivables turnover = Revenue ÷ Receivables
= $16,747,000K ÷ $2,558,000K
= 6.55
Based on the provided data, Boston Scientific Corp's receivables turnover ratio is unavailable for the years ending December 31, 2020, 2021, 2022, 2023, and 2024. This lack of information hinders a detailed analysis of the company's efficiency in collecting its accounts receivable within a specific period.
Further examination of this ratio in the future may provide insight into Boston Scientific Corp's effectiveness in managing its credit extending and collection processes.
Peer comparison
Dec 31, 2024
Company name
Symbol
Receivables turnover
Boston Scientific Corp
BSX
6.55
Abbott Laboratories
ABT
6.06
CONMED Corporation
CNMD
5.50
GE HealthCare Technologies Inc.
GEHC
5.21
Stryker Corporation
SYK
6.22